Global private equity and venture capital news and research

Posts Tagged ‘Orbimed Advisors’

7 January 2016

Existing VCs close $100m Series D in cancer testing provider Guardant

blood-75302_1280 OrbiMed Advisors has led a $100m Series D financing round in cancer testing provider Guardant Health alongside a number of existing venture capital firms.

7 May 2015

VC-backed Adaptimmune eyes $175m net IPO proceeds after Nasdaq debut

blood-cells_sq Venture capital-backed biotech business Adaptimmune Therapeutics is eyeing net proceeds of about $175m from its IPO after pricing its shares at $17 each.

30 October 2014

PE-backed Sientra raises $75m IPO

stock Private equity-backed breast implant seller Sientra has raised $75m for its IPO.

11 September 2014

OrbiMed beats target for second Asia fund with $300m final close

heart monitor medical healthcare Healthcare-focused private equity firm OrbiMed Advisors has held a $325m final close for its second fund aimed at the Asian market.

9 September 2014

Meritech Capital leads $35m Series A round for root canal company Sonendo

tooth teeth scan medical healthcare Meritech Capital Partners has led a $35m financing round for root canal therapy business Sonendo to boost its tech development, fund clinical studies and commercialise its Gentlewave system.

8 May 2014

NEA joins Aisling, OrbiMed to back cancer treatment business Loxo with $24m

life science test tube_sq Venture capital major New Enterprise Associates has led a $24m Series B financing round for cancer-focused biopharmaceutical business Loxo Oncology.

7 May 2014

Asia Development Bank commits $60m to healthcare firm Orbimed

The Asia Development Bank is to commit up to $60m to global healthcare investor OrbiMed Advisors’ latest fund targeting the region.

30 April 2014

Anti-ear disorder company Otonomy attracts more venture capital in $49m Series D

ear_lrg Venture-backed ear disorder treatment business Otonomy has picked up another $49m of funding through an oversubscribed Series D round.

22 April 2014

Vivo Capital leads $58.5m Series D for ProNAi Therapeutics

biotech_lrg Nucleic acid therapeutics developer ProNAi Therapeutics has secured $59.5m in a Series D round led by venture capital firm Vivo Capital.

13 March 2014

OrbiMed helps Sage Therapeutics raise $38m

medical monitor Healthcare-focused investment firm OrbiMed Advisors participated in a $38m Series C round for biopharmaceutical company Sage Therapeutics.

Page 1 of 3123

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016